NCT03959605 (ALAFOR) is a clinical trial of blood sample for genetic test in Albinism, Ocular, sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

Who is sponsoring NCT03959605?

NCT03959605 is sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

What drugs are being tested in NCT03959605?

Interventions in NCT03959605: blood sample for genetic test, Ophtalmological examination.

What condition does NCT03959605 study?

NCT03959605 studies Albinism, Ocular.

Is NCT03959605 still recruiting?

NCT03959605 is currently completed. Last updated 21 October 2021.

Last reviewed 2021-10-21 · How we verify

NCT03959605: ALAFOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genetic Determinant of Foveolar Hypoplasia in Parents of Albinos Children

Completed Last updated 21 October 2021

What this trial tests

trial testing blood sample for genetic test in Albinism, Ocular in 48 participants. Completed in 1 October 2021.

Timeline

6 January 2019

Primary endpoint
2 February 2021

1 October 2021

Quick facts

Lead sponsor	Fondation Ophtalmologique Adolphe de Rothschild
Status	Completed
Study type	OBSERVATIONAL
Enrollment	48
Start date	6 January 2019
Primary completion	2 February 2021
Estimated completion	1 October 2021
Sites	1 location across France

Drugs / interventions tested

blood sample for genetic test
Ophtalmological examination

Conditions studied

Albinism, Ocular — all drugs for Albinism, Ocular →

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild — full company profile →

Who can join

18 and older, any sex, with Albinism, Ocular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fovea plana could be the phenoyipic translation of a genetic anomaly in one of the genes identified in albinisme

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Albinism, Ocular

Currently open trials in the same condition.

NCT06345976 — Functional Impairment in Albinism · recruiting

Other Fondation Ophtalmologique Adolphe de Rothschild trials

Trials by the same sponsor.

NCT04701619 — Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE) · NA · not yet recruiting
NCT04763161 — Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Cas · not yet recruiting
NCT06264531 — Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous M · Phase 2, PHASE3 · recruiting
NCT06895044 — Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study · recruiting
NCT06644196 — Creation of a Database of Images of the Eye With the Holographic Doppler Laser · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03959605 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondation Ophtalmologique Adolphe de Rothschild
Last refreshed: 21 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03959605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing